Sagimet Biosciences Inc. (SGMT) stock
SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.22−0.71 (-6.50%)
Close on Nov 13, 2026Market cap $635.26MP/E –Yield –
Sagimet Biosciences total assets
Total assets on the balance sheet at the end of each period.
Sagimet Biosciences's total assets was $282.09M at Sep 30, 2026. For fiscal 2025 it was $116.48M, down 27.3% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.48M | -27.3% |
| FY2024 | Dec 31, 2024 | $160.26M | +65.7% |
| FY2023 | Dec 31, 2023 | $96.72M | +192.8% |
| FY2022 | Dec 31, 2022 | $33.03M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $282.09M | +119.7% |
| Q2 FY2026 | Jun 30, 2026 | $263.43M | +91.7% |
| Q1 FY2026 | Mar 31, 2026 | $107.76M | -26.3% |
| Q4 FY2025 | Dec 31, 2025 | $116.48M | -27.3% |
| Q3 FY2025 | Sep 30, 2025 | $128.40M | -26.5% |
| Q2 FY2025 | Jun 30, 2025 | $137.41M | -27.3% |
| Q1 FY2025 | Mar 31, 2025 | $146.17M | -24.9% |
| Q4 FY2024 | Dec 31, 2024 | $160.26M | +65.7% |
| Q3 FY2024 | Sep 30, 2024 | $174.78M | +69.8% |
| Q2 FY2024 | Jun 30, 2024 | $189.02M | +779.2% |
| Q1 FY2024 | Mar 31, 2024 | $194.53M | +488.9% |
| Q4 FY2023 | Dec 31, 2023 | $96.72M | – |
| Q3 FY2023 | Sep 30, 2023 | $102.93M | – |
| Q2 FY2023 | Jun 30, 2023 | $21.50M | – |
| Q4 FY2022 | Dec 31, 2022 | $33.03M | – |
See a number that looks wrong?